文献速递基础与转化研究临床试验与 GCP

CRISPR-Cas12a编辑HBG1/HBG2启动子治疗镰状细胞病

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.
PubMed 文献 · N Engl J Med · 2026-01-01

这项1-2期多中心开放标签单组研究纳入28例12-50岁重型镰状细胞病患者,单次输注reni-cel(CRISPR-Cas12a编辑自体造血干细胞)后中位随访9.5个月。27例中性粒细胞和血小板植入,6个月时总血红蛋白从基线9.8±1.7 g/dL升至13.8±1.9 g/dL,胎儿血红蛋白从2.5±2.5%升至48.1±3.2%;27/28例无血管闭塞事件。研究因申办方重新评估临床开发优先级而提前终止。

要点

  • reni-cel单次输注后6个月总血红蛋白和胎儿血红蛋白显著提升并维持。
  • 27/28例患者输注后未发生血管闭塞事件。
  • 安全性事件与白消安清髓和自体干细胞移植预期一致。

核心结论

  • reni-cel治疗使总血红蛋白正常化并提高胎儿血红蛋白百分比,28例中27例输注后无血管闭塞事件。
  • 结果支持进一步研究该基因编辑方法治疗重型镰状细胞病。

研究设计与样本

  • 1-2期、多中心、开放标签、单组研究,纳入12-50岁重型镰状细胞病患者,前2年每年至少2次严重血管闭塞事件。
  • 患者接受白消安清髓预处理后单次输注reni-cel,监测植入、血红蛋白相关指标、等位基因编辑水平、血管闭塞事件和不良事件24个月。
  • 研究基于申办方对临床开发优先级的重新评估而提前终止,报告的是非预设分析结果。

主要发现

  • 27例至数据截止日实现中性粒细胞和血小板植入,中性粒细胞植入中位23天(范围14-29),血小板植入中位25天(范围17-51)。
  • 18例有至少6个月数据的患者中,第6个月平均总血红蛋白从基线9.8±1.7 g/dL升至13.8±1.9 g/dL。
  • 第6个月平均胎儿血红蛋白百分比从基线2.5±2.5%升至48.1±3.2%,此后维持不低于上述值。
  • 1例患者输注后发生两次严重血管闭塞事件。
  • 不良事件与白消安清髓预处理和自体造血干细胞移植后预期事件一致。

临床怎么用

  • 该疗法为单次输注的自体基因编辑干细胞治疗,需白消安清髓预处理。
  • 治疗后可实现总血红蛋白正常化和胎儿血红蛋白显著升高,多数患者无血管闭塞事件。
  • 需监测植入时间及清髓移植相关不良事件。

局限性

  • 研究提前终止,报告的是非预设分析。
  • 中位随访仅9.5个月,长期疗效和安全性未确定。
  • 单组设计,样本量28例,无对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Renizgamglogene autogedtemcel (reni-cel) is an investigational clustered regularly interspaced short palindromic repeats (CRISPR)-Cas12a gene-edited autologous hematopoietic stem-cell therapy. The therapy was designed to disrupt the BCL11A binding sites in the HBG1 and HBG2 promoters to reactivate fetal hemoglobin production for the treatment of sickle cell disease. METHODS: We conducted a phase 1-2, multicenter, open-label, single-group study involving patients with severe sickle cell disease who were 12 to 50 years of age and had had at least two severe vaso-occlusive events per year in the previous 2 years. The patients received a single infusion of reni-cel after myeloablative conditioning with busulfan. The patients were monitored for engraftment, hemoglobin-related measures, allelic editing levels, vaso-occlusive events, and adverse events over a 24-month period. The study was terminated early on the basis of the sponsor's reassessment of clinical development priorities. Results of an analysis that was not prespecified are reported. RESULTS: As of October 29, 2024, a total of 28 patients with severe sickle cell disease had been treated with reni-cel. The median duration of follow-up was 9.5 months (range, 0.7 to 25.2). Among 27 patients who had neutrophil and platelet engraftment by the data-cutoff date, neutrophil engraftment occurred after a median of 23 days (range, 14 to 29), and platelet engraftment occurred after a median of 25 days (range, 17 to 51). At month 6, among 18 patients with at least 6 months of available data, the mean (±SD) total hemoglobin level (9.8±1.7 g per deciliter at baseline) had increased to 13.8±1.9 g per deciliter, and the mean percentage of fetal hemoglobin (2.5±2.5% at baseline) had increased to 48.1±3.2%; both measures were maintained at or above these values thereafter. One patient had two severe vaso-occlusive events after infusion. Adverse events were consistent with those that occur after myeloablative busulfan-based conditioning and autologous hematopoietic stem-cell transplantation. CONCLUSIONS: Treatment with reni-cel led to normalization of the total hemoglobin level and an increase in the percentage of fetal hemoglobin, with no vaso-occlusive events occurring in 27 of 28 patients after infusion. These results support further investigation of this gene-editing approach in the treatment of severe sickle cell disease. (Funded by Editas Medicine; RUBY ClinicalTrials.gov number, NCT04853576.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Hanna R, Frangoul H, Pineiro L, et al. CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. N Engl J Med. 2026. PMID: 41931047. doi:10.1056/NEJMoa2415550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。